IBD patients receiving immunomodulator comedication were compared to patients receiving dose optimization of the anti-TNF agent in order to reverse the immunogenic LOR; some previous studies suggest dose optimization of the existing anti-TNF agent to reduce ADA levels [32–36]. Here, ADA is linked to inflammatory bowel disease.